The mechanism has proven challenging, with GSK and iTeos becoming the latest companies to terminate an anti-TIGIT asset. Last month, BeiGene announced it was terminating development of ociperlimab, ...

A trial of MK-7648A for non small lung cancer (KEYVIBE 007) Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Please note - this trial is no longer recruiting patients. We hope to add results when they are available. Vibostolimab (MK-7648) is also an immunotherapy. It works by blocking a receptor that affects ...

Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

KeyVibe-007 is a randomized, double-blind phase 3 trial (ClinicalTrials.gov, NCT05226598 ) evaluating the fixed-dose combination of vibostolimab and pembrolizumab with chemotherapy in treatment-naïve ...

Merck is discontinuing the KeyVibe-003 and KeyVibe-007 studies evaluating the fixed-dose combination of vibostolimab, an anti-TIGIT antibody and Keytruda in a non-small cell lung cancer (NSCLC) ...

Merck is discontinuing the KeyVibe-003 and KeyVibe-007 studies evaluating the fixed-dose combination of vibostolimab, an anti-TIGIT antibody and Keytruda in a non-small cell lung cancer (NSCLC ...

Merck is discontinuing the Phase 3 KeyVibe-003 and KeyVibe-007 trials, which are evaluating the fixed-dose combination of vibostolimab and pembrolizumab in certain patients with non-small cell lung ...

Merck is discontinuing the Phase III KeyVibe-003 and KeyVibe-007 trials of vibostolimab and Keytruda in certain patients with non-small cell lung cancer, based on the recommendation of an independent ...